A Food and Drug Administration panel could soon help determine the fate of billions of dollars in household-name pain drugs such as Advil and Aleve over the question of which ones pose a greater cardiac risk.. An advisory committee of medical experts is expected to spend two days this week reaching a recommendation on whether the drug naproxen, sold as Aleve by Bayer AG, may carry little to no heart danger, giving it a possible boost over other anti-inflammatory drugs. 